Press Releases

 Filter by Provider

Dollar Tree, Inc. (NASDAQ: DLTR), will report financial results for the third quarter of fiscal year 2026 ended on October 31, 2026, before the stock market opens on Tuesday, November 24, 2026, followed by a conference call for investors and analysts at 8 a.m. ET. Chief Executive Officer Mike Creedon and Chief Financial Officer Stewart Glendinning will discuss the company’s results and lead a question-and-answer session.

Toast (NYSE: TOST), the global technology platform built for restaurants and retail businesses, today reported financial results for the third quarter ended September 30, 2026.

Mativ Holdings, Inc. (NYSE: MATV) today announced its participation in the following upcoming investor conference:

Sturm, Ruger & Company, Inc. (NYSE: RGR) will announce its financial results for the third quarter 2026 and file its Quarterly Report on Form 10-Q on Wednesday, November 4, 2026, after the close of the stock market.

Coupang, Inc. (NYSE: CPNG) today announced financial results for its third quarter ended September 30, 2026.

ZUG, Switzerland, Nov. 03, 2026 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (Oculis), a global biopharmaceutical company focused on breakthrough innovations to address significant unmet medical needs in neuro-ophthalmology and ophthalmology, today announced results for the third quarter ended September 30, 2026, and provided an overview of the Company’s progress.

MARYSVILLE, Ohio, Nov. 03, 2026 (GLOBE NEWSWIRE) -- The Scotts Miracle-Gro Company (NYSE: SMG), home to North America’s leading consumer lawn and garden brands, today announced that its Board of Directors has approved the payment of a cash dividend of $0.66 per share. The dividend is payable on Friday, December 4, 2026, to shareholders of record as of Friday, November 20, 2026.

NEW YORK, Nov. 03, 2026 (GLOBE NEWSWIRE) -- Teladoc Health, Inc. (NYSE:TDOC), the global leader in virtual care, today announced that it issued inducement awards to three new employees.

Over 3.07 million Paid Subscribers, up 2% over Q3 2025 

ALISO VIEJO, Calif., Nov. 03, 2026 (GLOBE NEWSWIRE) -- RxSight, Inc. (NASDAQ: RXST) today reported financial results for the quarter ended September 30, 2026.

Executing Against Transformational ROI Strategy for Long-Term Value Creation Reaffirming Full Year 2026 Outlook

Record Third Quarter Revenue of $361 Million, Up 20% YoY

Net Asset Value of $12.64 Per Share as of September 30, 2026

SAN JOSE, Calif., Nov. 03, 2026 (GLOBE NEWSWIRE) -- Astera Labs, Inc. (Nasdaq: ALAB), a leader in semiconductor-based connectivity solutions for rack-scale AI infrastructure, today announced financial results for the third quarter of fiscal year 2026, ended September 30, 2026.

AUSTIN, Texas, Nov. 03, 2026 (GLOBE NEWSWIRE) -- Mobia Medical, Inc. (Nasdaq: MOBI), a medical device company redefining stroke recovery for survivors living with life-altering motor impairments, today announced that members of management will participate in a fireside chat and host one-on-one investor meetings at the upcoming 8th Annual Wolfe Research Healthcare Conference in New York. The fireside chat will take place on Tuesday, November 10, 2026, at 12:20 p.m. Pacific Time / 3:20 p.m. Eastern Time.

Block, Inc. (NYSE: XYZ) has posted its results for the third quarter of 2026 on the Financials section of its Investor Relations website at investors.block.xyz. Block will host a conference call and earnings webcast at 2:00 p.m. Pacific Time / 5:00 p.m. Eastern Time today to discuss these financial results.

CINCINNATI, Nov. 03, 2026 (GLOBE NEWSWIRE) -- Phillips Edison & Company, Inc. (Nasdaq: PECO) (“PECO” or the “Company”), one of the nation’s largest owners and operators of high-quality, grocery-anchored neighborhood shopping centers, will host a virtual Business Update for the investment community on Wednesday, December 16, 2026, at 12:00 p.m. Eastern Time. The event will be webcast only.

Third Quarter 2026 Financial Highlights:

DENVER, Nov. 03, 2026 (GLOBE NEWSWIRE) -- InnovAge Holding Corp. (“InnovAge” or the “Company”) (Nasdaq: INNV), an industry leader in providing comprehensive healthcare programs to frail, predominantly dual-eligible seniors through the Program of All-inclusive Care for the Elderly (PACE), today announced financial results for its fiscal first quarter ended September 30, 2026.

NEW YORK, Nov. 03, 2026 (GLOBE NEWSWIRE) -- Strata Critical Medical, Inc. (Nasdaq: SRTA, “Strata” or the “Company”), today announced that management will present at the UBS Global Healthcare Conference on Tuesday, November 10th, 2026 at 12:30 pm ET. A webcast of the event will be available at the link here. A replay will be available shortly after the conclusion of the presentation on the investor relations section of the Company’s website at https://ir.stratacritical.com/.

FREMONT, Calif., Nov. 03, 2026 (GLOBE NEWSWIRE) -- Alamar Biosciences, Inc. (Nasdaq: ALMR), a leader in precision proteomics dedicated to enabling the earliest detection of disease, today reported financial results for the quarter ended September 30, 2026.

VISTA, Calif., Nov. 03, 2026 (GLOBE NEWSWIRE) -- Flux Power Holdings, Inc. (NASDAQ: FLUX) (“Flux Power” or the “Company”), a leading developer of advanced lithium-ion energy storage solutions and fleet intelligence technology, today reported financial and operational results for the 2027 fiscal first quarter ended September 30, 2026.

Generated record XDEMVY® net product sales of $194.6 million in the third quarter, an increase of approximately 64% year-over-year

BOSTON, Nov. 03, 2026 (GLOBE NEWSWIRE) -- Amwell® (NYSE: AMWL), a leading provider of a comprehensive SaaS-based technology-enabled healthcare platform, today announced financial results for the third quarter ended September 30, 2026.

THOUSAND OAKS, Calif., Nov. 03, 2026 (GLOBE NEWSWIRE) -- Latigo Biotherapeutics, Inc. (Nasdaq: LTGO), a clinical-stage biopharmaceutical company committed to developing innovative non-opioid pain medicines, today announced that management will participate in the following investor conferences:

AUSTIN, Texas, Nov. 03, 2026 (GLOBE NEWSWIRE) -- TTEC Holdings, Inc. (NASDAQ: TTEC), a leading global technology, consulting and managed services company focused on delivering solutions at the intersection of data, AI, and customer experience, announced today that TTEC will release its earnings results after market close on Monday, November 9, 2026, when a press release will be issued. The Company will host a live webcast and conference call at 8:30 a.m. ET on Tuesday, November 10, 2026.

PONTE VEDRA, Fla., Nov. 03, 2026 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and other foot & ankle conditions, today announced it will present at the Stifel 2026 Healthcare Conference, Wednesday, November 11, 2026, beginning at approximately 1:20 pm ET.

Approximated TTM Subscription Revenue Contribution for ≥$30K ARR Customers Grew 18% year-over-year

Milwaukee, Wisconsin, Nov. 03, 2026 (GLOBE NEWSWIRE) -- Weyco Group, Inc. (NASDAQ: WEYS) (the “Company”) announced that today its Board of Directors declared a special cash dividend of $2.00 per share. The Company’s total cash outlay for this special dividend will be approximately $19 million. The dividend will be paid on January 8, 2027, to shareholders of record at the close of business on November 17, 2026.

SUNNYVALE, Calif., Nov. 03, 2026 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today reported financial results for the third quarter ended September 30, 2026.

SAN DIEGO, Nov. 03, 2026 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a transformative and broadly accessible pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune diseases, today announced that on November 2, 2026, the Company granted (i) non-qualified stock options to one newly-hired non-executive employee to purchase a total of 300,000 shares of the Company’s common stock at an exercise price per share of $2.01, which was the closing price per share of the Company’s common stock as reported by NASDAQ on November 2, 2026, and (ii) restricted stock units (RSUs) representing 87,000 shares of its common stock to two newly-hired non-executive employees, including the newly-hired employee receiving the non-qualified stock options referenced above. The grants were approved by the Compensation Committee of the Company’s Board of Directors and granted under the Company’s Amended and Restated Inducement Equity Plan as an inducement material to the new employees entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4). The options will vest over four years, with 25% of the shares underlying the option vesting on the one-year anniversary of the grant date and the remaining 75% vesting in approximately equal monthly installments over the following thirty-six months, subject to the employee being continuously employed by the Company through each vesting date. The RSUs will vest over four years, with 25% of the shares underlying each RSU award vesting on each anniversary of the grant date, subject to the employees being continuously employed by the Company through each vesting date.

SAN DIEGO, Nov. 03, 2026 (GLOBE NEWSWIRE) -- Cibus, Inc. (Nasdaq: CBUS), a technology company that uses biology to produce sustainable ingredients and helps farmers grow more food with fewer inputs, today announced that the company will report third quarter 2026 financial results on Thursday, November 12, 2026. Cibus’ management team will host a conference call and audio webcast at 4:30 p.m. ET on that day to discuss the financial results and other company updates.

SAN JOSE, Calif., Nov. 03, 2026 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX), a worldwide leader in innovative laser-based medical systems, delivery devices, and accessories for the treatment of glaucoma and retinal diseases, today announced plans to release financial results for the third quarter 2026 and provide a business update after the close of trading on November 17, 2026.

ROCKVILLE, MD, Nov. 03, 2026 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on developing innovative antibody-based therapeutics for the treatment of cancer, today announced the appointments of Emil Kuriakose, M.D. and Michael Vasconcelles, M.D. as independent directors to its Board of Directors, effective October 30, 2026.

Alamar’s NULISAseq™ Immune 340 and NULISAseq™ Neuro 220 panels will be used to investigate disease progression, biological subtypes and treatment response

Additional coverage helps dealers serve a broader credit spectrum including near-prime customers

The combination brings together EIS' AI-native core platform and deep insurance expertise with Amdocs' aOS, scale and transformation capabilities

YTD Net Income Increased from $21.0 Million to $24.2 MillionCompany Records 15th Consecutive Profitable Quarter

AUDUBON, Pa., Nov. 03, 2026 (GLOBE NEWSWIRE) -- Globus Medical, Inc. a leading musculoskeletal technology company, today announced that it completed the acquisition of Synaptive Medical, deepening the Company's presence in cranial neurosurgery and positioning it for further growth in this market.

BOSTON, Nov. 03, 2026 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing a potentially transformative first-in-class therapy for patients with ocular cancers, today announced that Natalie Holles, CEO and President, will participate in the following upcoming investor conference:

The Manitowoc Company, Inc. (NYSE: MTW) (the “Company” or “Manitowoc”) today reported third-quarter net income of $11.0 million, or $0.30 per diluted share. Third-quarter adjusted net income(1) was $11.5 million or $0.31 per diluted share.

Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a leading rare disease company, today reported financial results for the third quarter 2026 and provided a business update.

SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Nov. 03, 2026 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing and commercializing treatments that address mechanisms of therapeutic resistance, today announced that management will be participating in the following investor conferences in November:

SOUTH SAN FRANCISCO, Calif., Nov. 03, 2026 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (Nasdaq: DNLI) today reported financial results for the third quarter ended September 30, 2026, and provided business highlights.

Third quarter net income of $1.34 per diluted shareand adjusted operating income of $1.34 per diluted share

Announced positive topline induction data for SPY003 from Part A of the Phase 2 SKYLINE trial (“SKYLINE”), completing proof-of-concept for all three monotherapies in inflammatory bowel disease (“IBD”). SKYLINE Part B is enrolling ahead of schedule, enabling the Company to increase enrollment and provide topline induction results for three potential best-in-indication combinations, which are expected in Q3 2027

Q3 2026 total product revenue of $125.5 million, reflecting 19% growth year-over-year

IRVINE, Calif., Nov. 03, 2026 (GLOBE NEWSWIRE) -- Skyworks Solutions, Inc. (Nasdaq: SWKS), a global leader in high-performance RF, precision timing, power management and mixed-signal solutions, today reported fourth fiscal quarter and fiscal year 2026 results for the period ended Oct. 2, 2026.